Timothy Hong Man To

Timothy Hong Man To

Auto-generated profile, based on publicly available information

Timothy Hong Man To

Southern Adelaide Palliative Services, Repatriation General Hospital, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2011 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JBJacqueline A Bowden
Jacqueline A Bowden
TTTimothy Hm To
Timothy Hm To
AAAmy P Abernethy
Amy P Abernethy
DCDavid C Currow
David C Currow
Breathlessness causes significant burden in our community but the underlying socio-demographic and lifestyle factors that may influence it are not well quantified. This study aims to define these predictors of chronic breathlessness at a population level.

17 November 2016 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
JTJennifer Tieman
Jennifer Tieman
KSKate Swetenham
Kate Swetenham
DMDeidre Morgan
Deidre Morgan
TTTimothy H. To
Timothy H. To
DCDavid C. Currow
David C. Currow
Telehealth is being used increasingly in providing care to patients in the community setting. Telehealth enhanced service delivery could offer new ways of managing load and care prioritisation for palliative care patients living in the community. The study assesses the feasibility of a telehealth-based model of service provision for community based palliative care patients, carers and clinicians. This study was a prospective cohort study of a telehealth-based intervention for community based patients of a specialist palliative care service living in Southern Adelaide, South Australia. Participants were 43 community living patients enrolled in the Southern Adelaide Palliative Service. To be eligible patients needed to be over 18 years and have an Australian modified Karnofksy Performance Score > 40. Exclusion criteria included a demonstrated inability to manage the hardware or technology (unless living with a carer who could manage the technology) or non-English speaking without a suitable carer/proxy. Participants received video-based conferences between service staff and the patient/carer; virtual case conferences with the patient/carer, service staff and patient’s general practitioner (GP); self-report assessment tools for patient and carer; and remote activity monitoring (ACTRN12613000733774). The average age of patients was 71.6 years (range: 49 to 91 years). All 43 patients managed to enter data using the telehealth system. Self-reported data entered by patients and carers did identify changes in performance status leading to changes in care. Over 4000 alerts were generated. Staff reported that videocalls were similar (22.3%) or better/much better (65.2%) than phone calls and similar (63.1%) or better/much better (27.1%) than face-to-face. Issues with the volume of alerts generated, technical support required and the impact of service change were identified. The trial showed that patients and carers could manage the technology and provide data that would otherwise not have been available to the palliative care service. Australian New Zealand Clinical Trials Registry ACTRN12613000733774 registered on 02/07/2013.

1 March 2012 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
DCDavid C. Currow
David C. Currow
DRDebra Rowett
Debra Rowett
MDMatthew Doogue
Matthew Doogue
TTTimothy H.M. To
Timothy H.M. To
AAAmy P. Abernethy
Amy P. Abernethy
Medication registration currently requires evidence of safety and efficacy from adequately powered phase 3 studies. Pharmacovigilance (phase 4 studies, postmarketing data, adverse drug reaction reporting) provide data on more widespread and longer term use. Historically, voluntary reporting systems for pharmacovigilance have had low reporting rates, relying on ad hoc reporting and retrospective chart reviews, or prospective registries have often been limited to specific drugs or clinical conditions. Furthermore, these data are often irrelevant in hospice and palliative care due to the timeliness of which such data become available and the unique characteristics of our population and prescribing: compounding comorbidities, progressive organ failure, accumulation of symptom-specific medications, tendency to attribute toxicity to disease progression, use of old, off-patent medications, and incorporation of evolving evidence. There is a need for prospective, systematic pharmacovigilance in hospice and palliative care. Here we describe an international, Web-based, 128-bit secure initiative to collect pharmacovigilance data documenting net clinical benefit and safety of common medications. The intention is for a diverse and large group of clinical units to record data prospectively on a small deidentified consecutive cohort of patients started on the medication of interest. A new medication would be studied every 3 months. Three key time points (different for each medication) will be assessed for each patient, collecting easily codefiable data at baseline, a point at which clinical benefit should be experienced, and a point at which short- to medium-term toxicities may occur. Toxicities can additionally be recorded at any time they occur. Data collection will take a maximum of 10 minutes per patient. The intention is to create an efficient, relevant system to improve hospice and palliative care with maximally generalizable results.

1 October 2017 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
TTTimothy H.M. To
Timothy H.M. To
TLThomas W. LeBlanc
Thomas W. LeBlanc
PEPeter Eastman
Peter Eastman
KNKaren Neoh
Karen Neoh
MAMeera R. Agar
Meera R. Agar
DCDavid C. Currow
David C. Currow
Background: Red Blood Cell (RBC) transfusions are commonly used in palliative care. RBCs are a finite resource, transfusions carry risks, and the net effect (benefits and harms) is poorly defined for people with life-limiting illnesses. Objective: To examine the indications and effects of RBC transfusion in palliative care patients. Design: This international, multisite, prospective consecutive cohort study. Setting/Subjects: Palliative care patients undergoing RBC transfusion. Measurements: Target symptoms (fatigue, breathlessness, generalized weakness, or dizziness) were assessed before transfusion and at day 7 by treating clinicians, using National Cancer Center Institute Common Terminology Criteria for Adverse Events. Assessment of harms was made at day 2. Results: One hundred and one transfusions with day 7 follow-up were collected. Median age was 72.0 (interquartile range 61.5–83.0) years, 58% men, and mean Australia-modified Karnofsky Performance Status (AKPS) of 48 (standard deviation [SD] 17). A mean 2.1 (SD 0.6) unit was tranfused. The target symptoms were fatigue (61%), breathlessness (16%), generalized weakness (12%), dizziness (6%), or other (5%). Forty-nine percent of transfusions improved the primary target symptom, and 78% of transfusions improved at least one of the target symptoms. Harms were infrequent and mild. An AKPS of 40%–50% was associated with higher chances of symptomatic benefit in the target symptom; however, no other predictors of response were identified. Conclusions: In the largest prospective consecutive case series to date, clinicians generally reported benefit, with minimal harms. Ongoing work is required to define the optimal patient- and clinician-reported hematological and functional outcome measures to optimize the use of donor blood and to minimize transfusion-associated risk.

1 November 2012 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
TTTimothy H.M. To
Timothy H.M. To
KCKatherine Clark
Katherine Clark
LLLawrence T. Lam
Lawrence T. Lam
TSTania Shelby-James
Tania Shelby-James
DCDavid Christopher Currow
David Christopher Currow

1 March 2019 in Journal of Geriatric Oncology
Verified
Journal Article
Open access
TTTimothy H.M. To
Timothy H.M. To
WSWee Kheng Soo
Wee Kheng Soo
HLHeather Lane
Heather Lane
AKAdnan Khattak
Adnan Khattak
CSChristopher Steer
Christopher Steer
JPJane Louise Phillips
Jane Louise Phillips
Geriatric assessment (GA) is a multidimensional health assessment of the older person to evaluate their physical and cognitive function, comorbidities, nutrition, medications, psychological state, and social supports. GA may help oncologists optimise care for older patients with cancer. The aim of this study was to explore the views of Australian medical oncologists regarding the incorporation of geriatric screening tools, GA and collaboration with geriatricians into routine clinical practice. Members of the Medical Oncology Group of Australia were invited to complete an online survey that evaluated respondent demographics, practice characteristics, treatment decision-making factors, use of GA, and access to geriatricians. Sixty-nine respondents identified comorbidities, polypharmacy, and poor functional status as the most frequent challenges in caring for older patients with cancer. Physical function, social supports and nutrition were the most frequent factors influencing treatment decision-making. The majority of respondents perceived value in GA and geriatrician review, although access was a barrier for referral. Such services would need to be responsive, providing reports within two weeks for the majority of respondents. Despite an emerging evidence base for the potential benefits of GA and collaboration with geriatricians, medical oncologists reported a lack of access but a desire to engage with these services.